XM không cung cấp dịch vụ cho cư dân của Mỹ.
S
S

Sanofi


Tin tức

Boehringer Ingelheim faces second hung jury in Chicago Zantac trial

UPDATE 1-Boehringer Ingelheim faces second hung jury in Chicago Zantac trial Hung jury in latest Zantac cancer trial in Chicago Boehringer Ingelheim only defendant after settlements with GSK, Pfizer FDA pulled Zantac in 2020 over NDMA carcinogen concerns Updates Sept 18 story with statement from Boehringer Ingelheim in paragraph 5 By Brendan Pierson Sept 18 (Reuters) - The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, as j
G
P
S

Boehringer Ingelheim faces second hung jury in Chicago Zantac trial

UPDATE 1-Boehringer Ingelheim faces second hung jury in Chicago Zantac trial Hung jury in latest Zantac cancer trial in Chicago Boehringer Ingelheim only defendant after settlements with GSK, Pfizer FDA pulled Zantac in 2020 over NDMA carcinogen concerns Updates Sept 18 story with statement from Boehringer Ingelheim in paragraph 5 By Brendan Pierson Sept 18 (Reuters) - The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, as j
G
P
S

A second Zantac cancer trial ends with hung jury

A second Zantac cancer trial ends with hung jury Hung jury in latest Zantac cancer trial in Chicago Boehringer Ingelheim only defendant after settlements with GSK, Pfizer FDA pulled Zantac in 2020 over NDMA carcinogen concerns By Brendan Pierson Sept 18 (Reuters) - The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, as jurors in Chicago were unable to agree on whether Boehringer Ingelheim must pay damages to an Illinois man
G
P
S

GSK settles two California lawsuits related to heartburn drug Zantac

UPDATE 1-GSK settles two California lawsuits related to heartburn drug Zantac Adds background and context Sept 18 (Reuters) - British drugmaker GSK GSK.L said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued heartburn drug Zantac caused cancer. GSK does not admit to any liability in either settlement, it said in a statement.
G
P
S

Auction Technology, Compass, D'Ieteren Group

EUROPE RESEARCH ROUNDUP-Auction Technology, Compass, D'Ieteren Group Sept 17 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Auction Technology, Compass Group and D'Ieteren Group on Tuesday. HIGHLIGHTS * Auction Technology Group Plc ATG.L : JP Morgan raises to overweight from neutral * Compass Group CPG.L : RBC cuts to sector perform from outperform * D'Ieteren Group SA IETB.BR : Jefferies cuts to hold from buy * Hermes HRMS.PA : Ex
B
B
B
C
D
E
E
E
E
H
H
L
L
N
R
R
R
S
S

Indian shares hold near record highs ahead of Fed policy decision

INDIA STOCKS-Indian shares hold near record highs ahead of Fed policy decision Updates at 10:16 a.m. IST By Bharath Rajeswaran BENGALURU, Sept 17 (Reuters) - Indian shares held ground near all-time highs on Tuesday, with traders expecting marginal moves ahead of the U.S. Federal Reserve's widely expected interest rate cut a day later. The Nifty 50 index .NSEI had dipped 0 .05% at 25,37 1.2 points, while the S&P BSE Sensex .BSESN had slipped 0.0 6 % at 82,9 39.94 , as of 1 0:16 a.m.
S

India's Panacea Biotec hits upper circuit on settlement with Sanofi India's unit

BUZZ-India's Panacea Biotec hits upper circuit on settlement with Sanofi India's unit ** Shares of Panacea Biotec PNCA.NS hit upper circuit of 5% at 349.79 ** Co reached settlement with Sanofi Healthcare India in suit seeking to restrain Sanofi India's SANO.NS unit from marketing a fully liquid hexavalent vaccine ** SANO will not commercially launc
S

Indian shares flat at the open ahead of Fed policy decision

INDIA STOCKS-Indian shares flat at the open ahead of Fed policy decision Updates at 9:25 a.m. IST BENGALURU, Sept 17 (Reuters) - Indian shares opened flat on Tuesday, with traders expecting marginal moves ahead of a likely interest rate cut by the U.S. Federal Reserve a day later. The Nifty 50 index .NSEI was up 0.02% at 25,385 points, while the S&P BSE Sensex .BSESN was little changed at 82,977.51, as of 9:25 a.m.
S

Indian shares set to open higher

INDIA STOCKS-Indian shares set to open higher BENGALURU, Sept 17 (Reuters) - Indian shares are set to open higher on Tuesday, with traders expecting incremental gains ahead of the U.S. Federal Reserve's expected rate cut a day later. The GIFT Nifty GIFc1 was at 25,476.5 points, as of 07:58 a.m. IST, indicating the NSE Nifty 50 .NSEI will open above Monday's closing level of 25,383.75. Both the benchmarks Nifty 50 and S&P BSE Sensex .BSESN hit record highs on Monday, underpinned by rising metal s
G
S

Sanofi, AstraZeneca win US approval for RSV therapy manufacturing line

UPDATE 1-Sanofi, AstraZeneca win US approval for RSV therapy manufacturing line Adds details on supply in paragraphs 4 and 6, background throughout Sept 16 (Reuters) - Sanofi SASY.PA and partner AstraZeneca AZN.L have received approval from the U.S. Food and Drug Administration for a manufacturing line for their preventive respiratory syncytial virus (RSV) therapy, the French drugmaker said on Monday.
A
S

US FDA approves manufacturing line for Sanofi's preventive RSV therapy

US FDA approves manufacturing line for Sanofi's preventive RSV therapy Sept 16 (Reuters) - Sanofi SASY.PA said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca's AZN.L preventive respiratory syncytial virus (RSV) therapy. Reporting by Sriparna Roy in Bengaluru; Editing by Shreya Biswa
A
S

MTU Aero Engines, Nestle, Vusiongroup

EUROPE RESEARCH ROUNDUP- MTU Aero Engines, Nestle, Vusiongroup Sept 16 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including MTU Aero Engines, Nestle and Vusiongroup, on Monday. HIGHLIGHTS * Advanced Medical Solutions Group Plc AMSU.L : Peel Hunt raises target to 246p from 220p * MTU Aero Engines AG MTXGn.DE : Citigroup cuts to sell from neutral * Nestle SA NESN.S : Morgan Stanley cuts to underweight from equal-weight * Sodexo EXHO.PA : B
A
A
B
B
C
D
I
I
M
M
N
N
S
A
A
P

French and Benelux stocks-Factors to watch

French and Benelux stocks-Factors to watch Sept 16 (Reuters) - Below are company-related news and stories from France and Benelux which could have an impact on the region's markets or individual stocks. REXEL RXL.PA : QXO QXO.O , the company billionaire Brad Jacobs is seeking to launch into building services, recently made an offer of around $9.4 billion to acquire Rexel RXL.PA that the French company on Sunday said it had rebuffed .
R
R
S
F
N
U

US FDA approves Eli Lilly's drug for eczema

UPDATE 2-US FDA approves Eli Lilly's drug for eczema Adds details on disease in paragraph 3, patient population in paragraph 6, other treatments in paragraphs 7-8, details on drug in paragraphs 8-9 Sept 13 (Reuters) - Eli Lilly LLY.N said on Friday the U.S. Food and Drug Administration approved its eczema drug for use in adults and children above 12 years old.
P
R
S

Regeneron and Sanofi win another U.S regulatory approval for their Dupixent product

BRIEF-Regeneron and Sanofi win another U.S regulatory approval for their Dupixent product Sept 13 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O /SANOFI SASY.PA : DUPIXENT® (DUPILUMAB) APPROVED IN THE U.S. AS FIRST AND ONLY TREATMENT FOR ADOLESCENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP) Regeneron Pharmaceuticals and Sanofi today announced that the U.S.
R
S

Sanofi-Aventis Canada Says DUPIXENT Approved In Canada For Treatment Of Children Aged 1 Year & Older With Eosinophilic Esophagitis

BRIEF-Sanofi-Aventis Canada Says DUPIXENT Approved In Canada For Treatment Of Children Aged 1 Year & Older With Eosinophilic Esophagitis Sept 12 (Reuters) - Sanofi SA SASY.PA : SANOFI-AVENTIS CANADA: DUPIXENT® (DUPILUMAB INJECTION) APPROVED IN CANADA FOR TREATMENT OF CHILDREN AGED 1 YEAR & OLDER WITH EOSINOPHILIC ESOPHAGITIS Source text for Eikon:
S

Moderna forecasts lower sales next year, shares slide to four-year low

UPDATE 4-Moderna forecasts lower sales next year, shares near four-year low Adds executive comment in paragraph 7 By Patrick Wingrove Sept 12 (Reuters) - Moderna MRNA.O pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key products and predicted 2025 sales below its forecast for the current year, sending its shares closer to a four-year low.
P
S

Moderna expects up to $3.5 billion in 2025 sales

Moderna expects up to $3.5 billion in 2025 sales By Patrick Wingrove Sept 12 (Reuters) - Moderna MRNA.O on Thursday said it expects sales of between $2.5 billion and $3.5 billion next year, and forecast that new product launches would drive an average annual growth rate of 25% in revenue between 2026 and 2028. The vaccine maker last month projected sales of $3 billion and $3.5 billion for this year, which will be its lowest annual revenue since Moderna launched its COVID-19 vaccine in late 2020
P
S

Sanofi, RadioMedix, and Orano Med announce licensing agreement on treatment for rare cancers

BRIEF-Sanofi, RadioMedix, and Orano Med announce licensing agreement on treatment for rare cancers Sept 12 (Reuters) - Sanofi SA SASY.PA : PRESS RELEASE: SANOFI, RADIOMEDIX, AND ORANO MED ANNOUNCE LICENSING AGREEMENT ON NEXT-GENERATION RADIOLIGAND MEDICINE FOR RARE CANCERS SANOFI, RADIOMEDIX, AND ORANO MED ANNOUNCE LICENSING AGREEMENT ON NEXT-GENER
S

India's global centre market to grow to $105 billion by 2030, says Nasscom-Zinnov report

India's global centre market to grow to $105 billion by 2030, says Nasscom-Zinnov report By Haripriya Suresh BENGALURU, Sept 11 (Reuters) - The market size of India's global capability centres (GCCs) is likely to grow to $99 billion-$105 billion by 2030 from $64.6 billion in fiscal 2024, according to a report by IT industry body Nasscom and consulting firm Zinnov released on Wednesday.
C
S



Các điều kiện

Các tài sản phổ thông

Khước từ trách nhiệm: các tổ chức thuộc XM Group chỉ cung cấp dịch vụ khớp lệnh và truy cập Trang Giao dịch trực tuyến của chúng tôi, cho phép xem và/hoặc sử dụng nội dung có trên trang này hoặc thông qua trang này, mà hoàn toàn không có mục đích thay đổi hoặc mở rộng. Việc truy cập và sử dụng như trên luôn phụ thuộc vào: (i) Các Điều kiện và Điều khoản; (ii) Các Thông báo Rủi ro; và (iii) Khước từ trách nhiệm toàn bộ. Các nội dung như vậy sẽ chỉ được cung cấp dưới dạng thông tin chung. Đặc biệt, xin lưu ý rằng các thông tin trên Trang Giao dịch trực tuyến của chúng tôi không phải là sự xúi giục, mời chào để tham gia bất cứ giao dịch nào trên các thị trường tài chính. Giao dịch các thị trường tài chính có rủi ro cao đối với vốn đầu tư của bạn.

Tất cả các tài liệu trên Trang Giao dịch trực tuyến của chúng tôi chỉ nhằm các mục đích đào tạo/cung cấp thông tin và không bao gồm - và không được coi là bao gồm - các tư vấn tài chính, đầu tư, thuế, hoặc giao dịch, hoặc là một dữ liệu về giá giao dịch của chúng tôi, hoặc là một lời chào mời, hoặc là một sự xúi giục giao dịch các sản phẩm tài chính hoặc các chương trình khuyến mãi tài chính không tự nguyện.

Tất cả nội dung của bên thứ ba, cũng như nội dung của XM như các ý kiến, tin tức, nghiên cứu, phân tích, giá cả, các thông tin khác hoặc các đường dẫn đến trang web của các bên thứ ba có trên trang web này được cung cấp với dạng "nguyên trạng", là các bình luận chung về thị trường và không phải là các tư vấn đầu tư. Với việc các nội dung đều được xây dựng với mục đích nghiên cứu đầu tư, bạn cần lưu ý và hiểu rằng các nội dung này không nhằm mục đích và không được biên soạn để tuân thủ các yêu cầu pháp lý đối với việc quảng bá nghiên cứu đầu tư này và vì vậy, được coi như là một tài liệu tiếp thị. Hãy chắc chắn rằng bạn đã đọc và hiểu Thông báo về Nghiên cứu Đầu tư không độc lập và Cảnh báo Rủi ro tại đây liên quan đến các thông tin ở trên.

Cảnh báo rủi ro: Vốn của bạn bị rủi ro. Các sản phẩm có đòn bẩy có thể không phù hợp với tất cả mọi người. Hãy xem kỹ Thông báo rủi ro của chúng tôi.